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Background: Cancer mortality peaked in the European Union (EU) in the late 1980s and declined thereafter.
Materials and methods: We analyzed EU cancer mortality data provided by the World Health Organization in
1970–2003, using joinpoint analysis.
Results: Overall, cancer mortality levelled off in men since 1988 and declined in 1993–2003 (annual percent change,
APC = 21.3%). In women, a steady decline has been observed since the early 1970s. The decline in male cancer
mortality has been driven by lung cancer, which levelled off since the late 1980s and declined thereafter (APC = 2.7%
in 1997–2003). Recent decreases were also observed for other tobacco-related cancers, as oral cavity/pharynx,
esophagus, larynx and bladder, as well as for colorectal (APC = 20.9% in 1992–2003) and prostate cancers
(APC = 21.0% in 1994–2003). In women, breast cancer mortality levelled off since the early 1990s and declined
thereafter (APC = 21.0% in 1998–2003). Female mortality declined through the period 1970–2003 for colorectal and
uterine cancer, while it increased over the last three decades for lung cancer (APC = 4.6% in 2001–2003). In both
sexes, mortality declined in 1970–2003 for stomach cancer and for a few cancers amenable to treatment.
Conclusion: This update analysis of the mortality from cancer in the EU shows favorable patterns over recent years in
both sexes.
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introduction
Total cancer mortality has peaked in the European Union (EU)
in the late 1980s and has declined from 1988 to 2002 by 15%
in both sexes, corresponding to the avoidance of >150 000
deaths per year in the early 2000s as compared with the rates
registered in the late 1980s [1–3]. These favorable trends were
largely due to the decline in three major neoplasms, i.e.
stomach with its long-term fall, intestines since the late 1990s
and lung in men. For men, a relevant contribution to this fall
was also given by other tobacco-related neoplasms, such as
larynx, oral cavity, esophagus and bladder. Further, there
were favorable trends for several neoplasms whose diagnosis
and/or treatment has improved, including not only (cervix)
uteri, testis, Hodgkin’s lymphoma (HL) and leukemia, but
also a few common neoplasms such as colorectum, breast
and prostate [1–3].
On the basis of recent trends in cancer mortality in the EU,
a projection was made of a further fall by 11% in age-
standardized cancer mortality from 2000 to 2015,
corresponding to additional 150 000 fewer deaths per year in
2015 as compared with the rates of 2000 [4].
To analyze and interpret recent patterns and monitor the
progress in cancer mortality in the EU, we updated trends to
2003, using also joinpoint regression analysis.
materials and methods
Cancer death certification data for the 27 EU member states (defined as in
January 2007) were derived from the World Health Organization (WHO)
database as available on electronic support, for the period 1970–2003 [5].
Data for Cyprus were not available. For EU rates computation, when
country data were missing for part of one or more calendar periods, data
replication of the last available year was made up to the end of the last
calendar period considered.
During the calendar period considered, four different revisions of the
International Classification of Diseases (ICD) were used. Classification of
cancer deaths was recoded, for all calendar periods, according to the ninth
revision of the ICD [6]. All intestinal cancers (including rectum) were
pooled together as all uterine cancers (cervix and endometrium).
Estimates of the resident population, on the basis of official censuses,
were obtained from the same WHO database [5].
From the matrices of certified deaths and resident population, we
computed age-specific rates for each 5-year age group and calendar year
and age-standardized mortality rates per 100 000 men and women—at all
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ages and truncated 35–64 years —using the direct method and on the basis
of the world standard population [7].
To identify significant changes in trend, we carried out joinpoint
regression analysis using the software provided by the Surveillance Research
Program of USA National Cancer Institute [8]. The aim of this analysis is to
identify possible points where a significant change in the linear slope of the
trend (in a log scale) is detected over the study period [9]. In joinpoint
analysis, the best fitting points, called ‘joinpoints’, are chosen where the rate
changes significantly. The analysis starts with the minimum number of
joinpoints (e.g. zero joinpoints, which is straight line), and tests whether
one or more joinpoints (up to three) are significant and must be added
to the model. Each significant joinpoint that indicates a change in the
slope (if any) is retained in the final model. To describe linear trends by
period, the estimated annual percent change (APC) is then computed for
each of those trends by fitting a regression line to the natural logarithm
of the rates using calendar year as a regressor variable.
results
Table 1 shows the overall age-adjusted mortality rates from
selected cancers per 100 000 men and women in the EU,
1982, 1992 and 2002, and the corresponding percent changes
in rates. In men, total cancer mortality was stable from 1982 to
1992 and declined by 13% from 1992 to 2002, from 185.5/
100 000 to 162.3. In women, it declined by 2% from 1982 to
1992 (from 107.1/100 000 to 104.7) and by 8% from 1992 to
2002 (to 95.8/100 000). In men, most cancers showed declines
in mortality, particularly from 1992 to 2002. These included
cancers of the oral cavity and pharynx (28%), esophagus
(27%), stomach (230%), intestines (27%), lung (222%) and
bladder (217%), but also gall-bladder (215%), larynx
(227%), testis (228%), kidney (213%), thyroid (223%),
HL (244%) and non-Hodgkin’s lymphoma (NHL) (24%) and
leukemias (28%). Similarly, in women during the last decade
there was a decline in the mortality from most cancers,
including those of the stomach (231%), intestines (216%),
breast (213%), uterus (220%), ovary (23%) and leukamias
(210%), but also gall-bladder (223%), bladder (214%),
kidney (217%), thyroid (228%), HL (238%) and
NHL (25%).
Table 2 gives corresponding values for truncated rates at
age 35–64 years. In middle-aged men, all cancer mortality
was approximately stable 240/100 000 from 1982 to 1992
and declined to 199.8 in 2002 (217%). In middle-aged
women, mortality declined from 159.1 to 152.5 from 1982
to 1992 (24%) and to 137.4 in 2002 (210%). In both
sexes, mortality from most cancers showed declines similar
to those observed for overall cancer mortality from 1992 to
2002.
Table 1. Overall age-adjusted (world population) mortality rates from selected cancers or groups of cancers per 100 000 men and women in the European
Union, around 1982 (in 1980–1984), 1992 (in 1990–1994) and in 2002, and corresponding percent changes in ratesa
Men Women
1982 1992 2002 Deathsa % change
1992/1982
% change
2002/1992
1982 1992 2002 Deathsa % change
1992/1982
% change
2002/1992
Oral cavity/pharynx 5.89 6.6 6.06 21 355 12.1 28.2 0.99 1.08 1.15 5671 9.1 6.5
Esophagus 5.63 5.83 5.4 20 746 3.6 27.4 1.17 1.16 1.14 6948 20.85 21.72
Stomach 18.91 13.99 9.75 40 759 226.0 230.3 8.78 6.36 4.41 27 980 227.56 230.66
Intestines 19.04 20.07 18.68 79 538 5.4 26.9 13.91 13.32 11.23 73 303 24.24 215.69
Liver 3.69 4.29 5.8 23 231 16.3 35.2 1.86 1.5 2.06 12 386 219.35 37.33
Gall-bladder/bile ducts 1.65 1.66 1.42 6009 0.6 214.5 2.66 2.43 1.88 11 583 28.65 222.63
Pancreas 7.19 7.59 7.62 30 758 5.6 0.4 4.29 4.76 4.99 30 843 10.96 4.83
Larynx 5.09 4.52 3.28 12 371 211.2 227.4 0.3 0.29 0.28 1317 23.33 23.45
Lung 51.99 52.76 40.97 165 280 1.5 222.3 8 9.66 11.34 58 574 20.75 17.39
Pleura 0.80 1.08 0.92 3560 35.0 214.8 0.29 0.3 0.24 1324 3.45 220.00
Bone 1.39 1 0.76 2443 228.1 224.0 0.75 0.53 0.42 1758 229.33 220.75
Connective/soft tissue 0.67 0.8 0.74 2476 19.4 27.5 0.5 0.62 0.56 2321 24.00 29.68
Skin including melanoma 1.93 2.23 2.31 8970 15.5 3.6 1.34 1.46 1.44 7833 8.96 21.37
Breast 0.22 0.27 0.27 878 22.7 0.0 20.21 20.85 18.05 89 575 3.17 213.43
Uterus (cervix/corpus) – – – – – – 8.44 7.03 5.63 27 806 216.71 219.91
Ovary – – – – – – 6.29 6.24 6.06 24 363 20.79 22.88
Prostate 13.43 14.92 13.97 66 960 11.1 26.4 – – – – – –
Testis 0.65 0.46 0.33 995 229.2 228.3 – – – – – –
Bladder 7.09 7.18 5.97 26870 1.3 216.9 1.51 1.5 1.29 9630 20.66 214.00
Kidney 4.07 4.75 4.15 16 061 16.7 212.6 1.91 2.12 1.77 10 032 10.99 216.51
Thyroid 0.43 0.4 0.31 1211 27.0 222.5 0.63 0.54 0.39 2341 214.29 227.78
Non-Hodgkin’s lymphomas 3.1 4.17 3.99 15 395 34.5 24.3 1.84 2.6 2.47 14 166 41.30 25.00
Hodgkin’s lymphoma 1.21 0.82 0.46 1614 232.2 243.9 0.66 0.48 0.3 1294 227.27 237.50
Multiple myeloma 1.7 2.04 2.2 9170 20.0 7.8 1.2 1.45 1.53 9279 20.83 5.52
Leukemias 6.07 5.7 5.23 20 419 26.1 28.2 4 3.58 3.22 17 405 210.50 210.06
All cancers, benign/malignant 183.45 185.42 162.3 666 300 1.1 212.5 107.12 104.66 95.84 537 909 22.30 28.43
aNumber of deaths in 2002.
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The findings from the joinpoint regression analysis over the
period 1970–2003 for selected cancers (overall and truncated
35–64 years) in the EU as a whole are given in Table 3 and
Figure 1 for men and Table 3 and Figure 2 for women. In men,
mortality from all cancers started to decline since 1988, with
a steeper decline in the last decade (APC = 21.3% from 1993
to 2003). Declines in mortality throughout the period
considered were observed for stomach cancer, bone, testis,
thyroid, HL and leukemias. More recent declines were observed
for oral cavity and pharynx (APC = 24.1% from 2001 to
2003), intestines (APC = 20.9% from 1992 to 2003), gall-
bladder (APC = 24.7% from 2000 to 2003), larynx
(APC = 24.3% from 1997 to 2003), lung (APC = 22.7% from
1997 to 2003), pleura (APC = 21.8% from 1992 to 2003),
connective and soft tissue sarcomas (APC = 21.2% from 1992
to 2003), prostate (APC = 21.0 from 1994 to 2003), bladder
(APC = 22.1 from 1992 to 2001 and 0.06 from 2001 to 2003),
kidney (APC = 21.8% from 1994 to 2003) and NHL
(APC = 21.3 from 1996 to 2003). Mortality tended to increase
throughout the period for liver, multiple myeloma and was
approximately stable for cancer of the esophagus and pancreas.
In women, all cancer mortality slightly declined throughout the
period considered (APC = 20.4 only from 1999 to 2003).
Continuous declines in trends were observed for stomach,
intestines, gall-bladder, pleura, bone, uterus, thyroid, HL and
leukemias. Declines in more recent years were observed for
breast cancer (APC = 21.0% from 1998 to 2003), connective
and soft tissue sarcomas (APC = 21.7 from 1993 to 2003),
kidney (APC = 22.2% from 1994 to 2003) and NHL
(APC = 22.1 from 1997 to 2003). Conversely, female mortality
increased throughout the period for cancers of the pancreas,
lung and multiple myeloma, and in the last two decades for
liver cancer, while it was approximately stable for oral cavity
and pharynx, esophagus, larynx, skin and bladder cancers. The
results of the joinpoint analysis for middle-aged men and
women were consistent with those for overall mortality.
discussion
This update analysis of the mortality from cancer in the EU
shows a favorable pattern over recent years in both sexes. In
terms of absolute number of deaths, this fall in age-adjusted
rates correspond to a levelling to 1.2 million deaths per
years over most recent calendar years [10, 11]. Total cancer
mortality started to level off in men from the EU since 1988 and
declined by 1.3% per year in the last 10 years, with larger
reductions in middle age. In women, a steady decline has been
observed since the early 1970s. The fall was of comparable
Table 2. Age-adjusted (world population) mortality rates from selected cancers or groups of cancers per 100 000 men and women aged 35–64 in the
European Union, in 1982 (in 1980–1984), 1992 (in 1990–1994) and in 2002, and corresponding percent changes in rates
Men Women
1982 1992 2002 Deathsa % change
1992/1982
% change
2002/1992
1982 1992 2002 Deathsa % change
1992/1982
% change
2002/1992
Oral cavity/pharynx 11.92 14.32 13.36 12 839 20.1 26.7 1.58 1.88 2.18 2179 19.0 16.0
Esophagus 9.29 10.05 9.15 8832 8.2 29.0 1.36 1.45 1.54 1567 6.62 6.21
Stomach 22.53 16.91 11.55 11 126 224.9 231.7 9.5 7.24 5.19 5190 223.79 228.31
Intestines 20.62 22.15 20.32 19 649 7.4 28.3 15.84 15.1 12.59 12 744 24.67 216.62
Liver 5.46 5.89 7.16 6793 7.9 21.6 2.5 1.88 2.3 2288 224.80 22.34
Gall-bladder/bile ducts 1.74 1.73 1.44 1335 20.6 216.8 2.96 2.6 1.99 1950 212.16 223.46
Pancreas 9.99 10.51 10.68 10 305 5.2 1.6 5.07 5.52 5.86 5961 8.88 6.16
Larynx 9.51 8.41 6 5793 211.6 228.7 0.51 0.51 0.54 543 0.00 5.88
Lung 77.18 77.9 56.49 54 645 0.9 227.5 12.82 14.83 18.59 18 704 15.68 25.35
Pleura 1.24 1.63 1.16 1059 31.5 228.8 0.42 0.42 0.34 323 0.00 219.05
Bone 1.88 1.34 0.89 852 228.7 233.6 0.9 0.6 0.41 413 233.33 231.67
Connective/soft tissue 0.91 1.11 0.97 890 22.0 212.6 0.7 0.87 0.84 803 24.29 23.45
Skin including melanoma 2.99 3.53 3.39 3245 18.1 24.0 2.1 2.33 2.22 2189 10.95 24.72
Breast 0.26 0.39 0.32 250 50.0 217.9 40.35 40.58 33.8 33 693 0.57 216.71
Uterus (cervix/corpus) – – – – – – 15.26 12.39 10.11 9982 218.81 218.40
Ovary – – – – – – 11.96 10.91 10.17 8275 28.78 26.78
Prostate 5.28 5.92 5.62 5451 12.1 25.1 – – – – – –
Testis 0.77 0.58 0.45 419 224.7 222.4 – – – – – –
Bladder 6.43 5.92 4.55 4411 27.9 223.1 1.28 1.17 1.01 1028 28.59 213.68
Kidney 6.06 6.69 5.54 5165 10.4 217.2 2.68 2.79 2.12 2065 4.10 224.01
Thyroid 0.65 0.58 0.43 400 210.8 225.9 0.82 0.65 0.43 418 220.73 233.85
Non-Hodgkin’s lymphomas 4.36 5.58 4.99 4700 28.0 210.6 2.49 3.33 2.99 2955 33.73 210.21
Hodgkin’s lymphoma 1.97 1.31 0.67 636 233.5 248.9 0.95 0.65 0.37 367 231.58 243.08
Multiple myeloma 2.01 2.29 2.22 2068 13.9 23.1 1.44 1.65 1.59 1563 14.58 23.64
Leukemias 6.32 5.8 4.89 4701 28.2 215.7 4.57 4.02 3.36 3349 212.04 216.42
All cancers, benign/malignant 240.3 240.92 199.79 192 821 0.3 217.1 159.09 152.53 137.4 137 814 24.12 29.92
aNumber of deaths in 2002.
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Table 3. Joinpoint analysis for selected cancer or groups of cancers, at all ages and truncated 35–64 years, in the European Union, 1970–2003a
Men Women
Trend 1 Trend 2 Trend 3 Trend 4 Trend 1 Trend 2 Trend 3 Trend 4
Years APC Years APC Years APC Years APC Years APC Years APC Years APC Years APC
All ages
Oral cavity/pharynx 1970–1984 2.07a 1984–1992 1.15a 1992–2001 20.97a 2001–2003 24.13a 1970–2000 0.91a 2000–2003 20.45
Esophagus 1970–1993 0.42a 1993–2001 21.22a 2001–2003 2.92 1970–2001 20.34a 2001–2003 7.46a
Stomach 1970–1993 23.03a 1993–2003 23.75a 1970–1984 23.68a 1984–1991 22.99a 1991–2003 23.76a
Intestines 1970–1992 0.63a 1992–2003 20.89a 1970–1991 20.13a 1991–2003 21.78a
Liver 1970–1982 2.15a 1982–1985 22.50 1985–2003 2.94a 1970–1982 20.64 1982–1986 28.17 1986–2003 2.40a
Gall-bladder/bile ducts 1970–1974 21.65 1974–1988 0.78a 1988–2000 21.12a 2000–2003 24.74a 1970–1972 25.13 1972–1987 20.14 1987–2001 22.00a 2001–2003 28.17
Pancreas 1970–1979 1.39a 1979–1982 20.21 1982–1987 1.35a 1987–2003 20.05 1970–1989 1.14a 1989–2003 0.39a
Larynx 1970–1976 1.75a 1976–1988 20.39a 1988–1997 22.26a 1997–2003 24.34a 1970–2003 20.48a
Lung 1970–1987 1.23a 1987–1997 20.95a 1997–2003 22.67a 1970–1987 2.46a 1987–2001 1.41a 2001–2003 4.60a
Pleura 1970–1976 1.26 1976–1987 4.66a 1987–1992 1.96 1992–2003 21.83a 1970–1975 23.19a 1975–1994 0.60a 1994–2003 22.76a
Bone 1970–1974 20.27 1974–2003 22.98a 1970–1975 21.64a 1975–1989 23.66a 1989–2003 22.34a
Connective/soft tissue 1970–1975 0.70 1975–1981 6.40a 1981–1992 1.89a 1992–2003 21.20a 1970–1977 1.49 1977–1980 9.80 1980–1993 2.25a 1993–2003 21.67a
Skin including melanoma 1970–1980 0.70a 1980–1987 2.53a 1987–2003 0.34a 1970–1993 0.70a 1993–2003 20.14
Breast 1970–1988 0.78a 1988–1995 20.46a 1995–1998 22.71a 1998–2003 21.03a
Uterus (cervix/corpus) 1970–1980 22.76a 1980–2003 22.01a
Ovary 1970–1994 0.03 1994–1999 21.50a 1999–2003 1.35
Prostate 1970–1982 0.51a 1982–1988 1.44a 1988–1994 0.41 1994–2003 21.01a
Testis 1970–1977 20.24 1977–1984 25.30a 1984–2003 23.07a
Bladder 1970–1979 1.25a 1979–1992 0.18a 1992–2001 22.13a 2001–2003 0.06 1970–1976 1.29a 1976–1993 20.23a 1993–1998 22.30a 1998–2003 20.18
Kidney 1970–1987 2.03a 1987–1994 1.17a 1994–2003 21.84a 1970–1994 0.94a 1994–2003 22.20a
Thyroid 1970–1977 0.13 1977–2000 21.03a 2000–2003 25.57a 1970–1977 20.04 1977–1987 22.39a 1987–1991 20.29 1991–2003 23.05a
Non-Hodgkin’s lymphoma 1970–1981 0.22 1981–1989 4.07a 1989–1996 0.92a 1996–2003 21.33a 1970–1981 0.20 1981–1988 5.15a 1988–1997 1.28a 1997–2003 22.08a
Hodgkin’s lymphoma 1970–1992 23.46a 1992–2003 25.29a 1970–1981 22.85a 1981–1985 25.68a 1985–1993 22.09a 1993–2003 24.82a
Multiple Myeloma 1970–1978 4.00a 1978–1981 22.93 1981–1987 3.97a 1987–2003 0.55a 1970–1977 4.06a 1977–1980 23.13 1980–1988 3.01a 1988–2003 0.42a
Leukemias 1970–1978 0.24 1978–1988 20.43a 1988–1996 21.05a 1996–2003 20.61a 1970–1982 20.44a 1982–2003 21.11a
All cancers, benign/malignant 1970–1988 0.37a 1988–1993 20.30 1993–2003 21.28a 1970–1981 20.50a 1981–1992 20.15a 1992–1999 21.14a 1999–2003 20.42a
35–64 years old
Oral cavity/pharynx 1970–1983 4.09a 1983–1992 1.81a 1992–2001 20.90a 2001–2003 24.86a 1970–1978 0.67 1978–1981 4.21 1981–2003 1.62a
Esophagus 1970–1985 1.88a 1985–1994 0.25 1994–2001 21.56a 2001–2003 1.58 1970–1987 20.24 1987–1993 1.57 1993–2001 20.40 2001–2003 7.74
Stomach 1970–1984 23.23a 1984–1988 22.13a 1988–1997 23.46a 1997–2003 24.44a 1970–1984 23.48a 1984–1991 22.40a 1991–2003 23.46a
Intestines 1970–1993 0.65a 1993–2003 21.24a 1970–1993 20.42a 1993–2003 22.08a
Liver 1970–1982 2.26a 1982–1985 22.68 1985–2003 1.90a 1970–1992 22.15a 1992–2003 1.72a
Gall-bladder/bile ducts 1970–1973 22.66 1973–1988 0.46a 1988–2000 21.21a 2000–2003 26.24a 1970–1989 20.68a 1989–2003 22.78a
Pancreas 1970–1987 0.95a 1987–2003 0.08 1970–2003 0.73a
Larynx 1970–1978 2.22a 1978–1988 20.25 1988–1997 22.54a 1997–2003 24.70a 1970–2003 0.00
Lung 1970–1988 1.15a 1988–1997 21.52a 1997–2003 23.38a 1970–1979 2.25a 1979–1998 1.52a 1998–2003 3.31a
Pleura 1970–1975 0.13 1975–1987 4.78a 1987–1992 1.24 1992–2003 23.38a 1970–2003 20.77a
Bone 1970–1975 0.11 1975–1997 23.19a 1997–2003 24.89a 1970–1975 20.32 1975–1979 26.69a 1979–2003 23.52a
Connective/soft tissue 1970–1976 0.67 1976–1979 11.41 1979–1992 2.27a 1992–2003 21.73a 1970–1993 3.25a 1993–2003 21.64a
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magnitude to that observed in the United States of America
since 1992 [12, 13], although somewhat larger in women
from the EU. The use of the joinpoint method of analysis has
allowed a detailed and accurate description of the pattern of
cancer mortality in recent years, since it identifies the calendar
years in which statistically significant changes in trends
occurred. This offers a clearer picture of actual trends in
mortality over long periods of time rather than using only
one trend statistic. The joinpoint regression and other similar
methods have been applied to age-adjusted cancer mortality
and incidence rates for different cancer sites by sex and race
and for truncated rates [12].
The role of major cancer sites in these trends, starting from
major tobacco-related ones, is described below.
In men, the decline in cancer mortality has been driven by
lung cancer mortality, which levelled off in the late 1980s and
declined thereafter, following the persistent reduction in
tobacco consumption in men from most European countries
[14]. Occupational, environmental as well as dietary factors
may also have exerted some favorable influence on these
favorable trends [15, 16]. Conversely, lung cancer mortality in
women from the EU has been steadily increasing, with even
stronger increase in the last years. This reflects the different
pattern in tobacco consumption in European women as
compared with men, with an increase in later calendar years,
and a persistent increment in recent years, particularly in some
European countries such as France and Spain [17, 18].
A contribution to the decline in male cancer mortality has
been given by the recent reduction in the mortality from
other tobacco-related cancers, including those of oral cavity/
pharynx, esophagus, larynx and bladder [19]. Male mortality
from oral and pharyngeal cancer peaked in the early 1990s
and levelled off thereafter, starting to decline—particularly in
middle-aged men—in most recent years [20]. For esophageal
cancer, the decrease in male mortality was less evident,
probably reflecting the greater importance of alcohol
consumption in this neoplasm, and the increase in
adenocarcinoma of the esophagus observed in various
countries mainly of northern Europe in recent years [21–23].
Trends were somewhat more favorable for male laryngeal
cancer, with an earlier (since the late 1980s) and larger
decline, likely reflecting the predominant role of tobacco in
laryngeal carcinogenesis [19, 24]. Bladder cancer mortality
started to level off in the early 1990s in men and even earlier in
women and declined thereafter. Mortality rates for male
bladder cancer well reflect the patterns of tobacco smoking for
subsequent generations of European men [19, 23]. Moreover,
a role in the fall has been played by reduced occupational
exposure to carcinogens, mainly aromatic amines. The
decreases in women are more difficult to explain. Better
control of urinary tract infections has probably played
a role, while the role of dietary and other potential urinary
tract carcinogens remains unquantified [23].
A significant influence on cancer mortality trends in EU is
given by the persistent fall of gastric cancer. Gastric cancer
mortality has been declining in the EU since several decades,
with no evidence of levelling off over recent years. A steady
reduction in gastric cancer mortality was observed in middle
age too, suggesting that the decline will continue in the nearT
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Figure 1. Joinpoint analysis for selected cancer mortality in men (all ages and aged 35–64 years) from the European Union, 1970–2002. Men, all ages
; Men, 35–64 years. .
original article Annals of Oncology
636 | Bosetti et al. Volume 19 | No. 4 | April 2008
Figure 2. Joinpoint analysis for selected cancer mortality in women (all ages and aged 35–64 years) from the European Union, 1970–2002. Women, all ages
; Women, 45–59 years .
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future. The reasons for this persistent decline are complex,
but almost certainly include a more varied and affluent diet,
better food conservation—including refrigeration—in
addition to the control of Helicobacter pylori infection and
reduced tobacco smoking [25, 26]. Whether improvements
in diagnosis and treatment have also played a role on the
favorable trends in gastric cancer throughout Europe,
particularly over most recent calendar periods, remain open
to evaluation [26].
A levelling off in mortality from intestinal cancer in men
from the EU—particularly in middle-aged ones—was observed
since the early 1990s, following the earlier favorable pattern
observed in women. The trends in colorectal cancer mortality
over recent years likely reflect favorable modifications in
(dietary) risk factors, although early diagnosis and treatment
of the disease may have had some effect on these trends
[27–29]. Hormone replacement therapy and other female
hormones may also have played a role in the fall of
colorectal cancer mortality in women and explain the
earlier and more favorable patterns observed in women as
compared with men [30].
A levelling and subsequent decline in breast cancer mortality
in the EU was first observed in the early 1990s, and has
continued in recent years, with a more evident reduction in
middle-aged women. The fall in breast cancer mortality is
largely attributable to advancements in therapy, but some role
of (mammographic) screening is also possible [28, 31].
Mortality from prostate cancer has been rising up to the late
1980s and declining since the mid-1990s. Improved treatment
is likely to have played a role, including earlier adoption of
transurethral resection of the prostate, as well as hormone
(androgen blockage) and radiotherapy for patients with locally
advanced disease [32]. It remains unclear whether—and to
which extent—the earlier rises in prostate cancer rates were due
to improved diagnosis and certification of prostate cancer, and
whether the recent falls have been influenced by earlier
diagnosis of the disease, including introduction of
prostate-specific antigen in Europe since the late 1980s.
With reference to other cancer sites, trends in liver cancer
mortality are extremely difficult to understand and interpret,
since the liver is one of the most common sites of secondaries,
and the distinction between primary and metastatic liver cancer
is variable across countries and calendar periods. Moreover,
mortality patterns differ widely across European countries. Still,
on a EU scale, the consistent trends in all-age and truncated 35–
64 years rates, but the different trends in the two sexes (steady
upwards in men, downwards first with subsequent rise in
women) probably reflect some real underlying trend, which has
to be related to the main recognized causes of liver cancer, i.e.
hepatitis B and C viruses and alcohol [33, 34]. Tobacco is
another recognized risk factor for liver cancer, but its
potential impact on national mortality rates remains difficult
to evaluate [19].
Mortality from cancers of the gall-bladder and bile ducts is
higher in women than in men, but rates have been declining in
EU women since the 1970s, the fall being larger over most
recent calendar years. Overall, male rates in the EU have
remained stable up to the early 2000s, but have started to
decline in the last years. The recent favorable trends in gall-
bladder cancer mortality essentially reflect the increase in
cholecystectomy, due to improvements in surgical techniques
(including laparoscopic cholecystectomy), since gallstones
are the major risk factor for the disease [35]. The trends may
have been also influenced by changes in diagnosis and
certification, nutrition and diet, antibiotic use, alcohol and
perhaps tobacco consumption [36].
Mortality from cancer of the pancreas rose for both sexes in
the EU up to the late 1980s, but has tended to level off
thereafter, particularly in men. At least part of the earlier trends
may be due to improved diagnosis and certification of the
disease, following the introduction of ultrasound, computed
tomography, endoscopic retrograde cholangiopancreatography
and fine-needle aspiration [37]. It is unlikely, however, that
these diagnostic improvements have played a major role over
more recent calendar periods, in consideration also of the
similar pattern of rates in middle age, i.e. when diagnosis and
certification is known to be more accurate. The favorable
trends recently observed mainly in men reflect the pattern of
cigarette smoking, confirming the relevant role of tobacco in
pancreatic carcinogenesis [19].
Trends for (mesothelioma) of the pleura are difficult to
interpret, since death certification data for this neoplasm are
subject to substantial uncertainties, given the difficulties in
diagnosis and certification validity [38]. These cautions
notwithstanding, it is nonetheless clear that the asbestos-related
pleural cancer epidemic is not anymore expanding in the EU,
some fall in rates being observed in the last decades, mostly in
middle-aged men. This pattern likely reflects the control of
asbestos use in Europe since the early 1970s and the changes in
the type of asbestos used in different European countries over
time [38, 39]. The apparent fall in pleural cancer mortality over
recent calendar years is largely spurious, and due to the recent
inclusion in the EU of Poland, Romania and other Eastern
European countries with low rates.
After the steady rise up to the late 1980s and early 1990s, skin
cancer rates tended to level off in EU men and women,
particularly in middle age. It appears therefore that control of
excessive sunshine exposure and sunburns has led to a levelling
in previous rises in mortality from skin cancers—mainly
melanomas—most clearly in young and middle-aged
population [40]. Better access to health care, earlier detection
of the disease, with consequent improved survival, could
also explain the improvement of mortality trends for skin
cancer [41].
Mortality from uterine cancer has been steadily declining
over the last few decades in the EU, mostly in young and
middle-aged women. Although it is not possible on the basis of
mortality data to distinguish between cervical and endometrial
cancer, this steady fall is likely due mainly to a decline in
cervical cancer mortality, following the adoption of cervical
screening [1, 28]. Mortality from cervical cancer remains,
however, high in several Central and Eastern European
countries [42].
After earlier rises, overall ovarian cancer mortality has
stabilized in the EU over the last three decades, while truncated
(35–64 years) mortality rates have tended to decline. The
appreciable declines in ovarian cancer mortality for middle-
aged women can be related to the changing prevalence of oral
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contraceptive use, which has a long-term favorable effect on
ovarian cancer risk [43]. The role of other risk factors for
ovarian cancer, as well as of improvements in diagnosis and
treatment (particularly for germ-cell neoplasms), and
consequently in survival, remains unquantified [44].
Mortality from testicular cancer has long been falling. These
favorable trends are mainly attributable to the adoption of
platinum-based therapy in the 1970s, which made testicular
cancer one of the neoplasms most amenable to treatment.
Substantial differences in mortality from this neoplasm were
found between Western and Eastern European countries, due
to different availability of the expensive drugs required to treat
testicular cancer [45]. There is therefore urgency for further
advancements in this largely avoidable cause of cancer death.
After earlier rises, mostly in men, kidney cancer mortality
rates have started to decline since the early 1990s in both sexes,
particular in middle-aged population. Kidney cancer is related
to tobacco smoking, though less strongly than respiratory or
bladder cancers [19]. It is also related to overweight and
hypertension [46]. Thus, the recent favorable pattern,
particularly in men, may be related to an earlier control of
tobacco (at least in men) and hypertension in several countries
of the EU [47].
Mortality from thyroid cancer—which is more common in
women than in men—tended to decline over the last three
decades, the falls being larger in women. Since thyroid cancer
incidence has been increasing, it is unclear how much of the
decline in mortality is due to better diagnosis of benign
thyroid nodules—which are the best recognized risk factor
for thyroid cancer—rather than to improved treatment of
thyroid neoplasms [48].
Mortality from HL has been declining in both men and
women from the EU, since this is a neoplasm highly amenable
to treatment [49]. The persistence of favorable trends over
the most recent calendar years indicates that continuing
progress in integrated treatment is still in course in several
countries of the EU. As for testicular cancer, there is still
scope for advancements in HL trends, particularly in several
Central and Eastern European countries.
In contrast with rates for HL, mortality from NHL has been
increasing in the EU up to the late 1990s, with a tendency to
decline only in more recent years. NHL is much less amenable
to treatment than HL. The earlier rises registered almost
certainly reflect real increases in disease incidence, although the
causes of these neoplasms remain largely undefined [50]. The
subsequent phases of the AIDS epidemic, the spread of hepatitis
C virus and the increased number of transplantations can, in
fact, explain only a limited proportion of the earlier rises.
Mortality from multiple myeloma has tended to rise until the
late 1980s in the EU, although in the more recent years rates
tended to levell off. Earlier upward trends were at least in part
attributed to advancements in the diagnosis of the disease [51].
Whether and to which extent the unfavorable trends in
mortality also reflect real rises in the incidence remains unclear.
Also the reasons for the recent decline remain largely
undefined, though improved treatment may have some role.
Mortality rates from leukemias steadily declined in both men
and women from the EU in the last decades. Leukemias include
a heterogeneous group of neoplasms, some of which—as
acute lymphoblastic leukemias of children and the young—are
largely amenable to treatment and consequently contribute to
the overall favorable trends observed [52].
In conclusion, mortality from most common cancers in the
EU showed a persistent favorable trend over more recent years.
The inclusion of data from former nonmarket economy
countries has led to some increases in absolute EU cancer
mortality rates and to some quantitatively less favorable trends
because the rates in Central and Eastern European countries
which entered the EU in 2004 and 2007 were higher than in the
preexisting EU member countries [2, 53]. In particular, Central
and Eastern European accession countries had the highest rates
not only for lung cancer and other tobacco-related cancers but
also for gastric, cervical cancer and leukemias [2, 11, 53].
Moreover, for all cancer sites, trends were more favorable in
the former 15 EU countries than in accession countries.
The maintenance—and potential improvement—of
favorable trends in cancer mortality in the EU in the near future
would therefore require a strategy focusing on the control of
tobacco and alcohol consumption, nutrition and diet and
avoiding excessive sun exposure [28]. Early diagnosis for selected
neoplasms—including cervix, breast, colorectum and perhaps
prostate—can also have a relevant impact. Universal adoption
of therapeutic advancements in various European
countries—mainly form Central and Eastern Europe—may
contribute to reduce the cancer mortality burden in the EU [2, 53].
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